Voit & Company’s GSK GSK Stock Holding History

Voit & Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,640	Closed	-$12K	–	71
2019 Q4	$12K	Buy	+4,640	New	+$258K	0.01%	60

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Voit & Company's GSK Position: Q2 2020 in Review

Voit & Company sold out of GSK (GSK) in Q2 2020, closing a stake of 6,916 shares — an estimated $328K sold.

Voit & Company first reported a position in GSK in Q4 2018 and held it in 6 quarters. The position peaked at $353K in Q4 2019. 841 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Voit & Company reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
Voit & Company sold 6,916 GSK shares in Q2 2020, an estimated $328K.
Voit & Company first reported a position in GSK in Q4 2018 and held it in 6 quarters.
Voit & Company's GSK position peaked at $353K in Q4 2019.
841 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Voit & Company's 13F filing for Q2 2020, filed 31 Jul 2020.